BG
RCKT icon

BlackRock Group’s Rocket Pharmaceuticals RCKT Stock Holding History

BlackRock Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$894K Sell
36,652
-48,200
-57% -$1.38M ﹤0.01% 2180
2016
Q3 		$3.22M Sell
84,852
-1,300
-2% -$40.9K ﹤0.01% 1326
2016
Q2 		$2.56M Hold
86,152
– – ﹤0.01% 1412
2016
Q1 		$2.55M Hold
86,152
– – ﹤0.01% 1388
2015
Q4 		$3.9M Hold
86,152
– – ﹤0.01% 1179
2015
Q3 		$3.24M Buy
+86,152
New +$3.96M ﹤0.01% 1254

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Group's RCKT Position: Q4 2016 in Review

BlackRock Group reduced its Rocket Pharmaceuticals (RCKT) stake by 57% in Q4 2016, selling an estimated $1.38M and leaving 36,652 shares worth $894K. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

BlackRock Group first reported a position in RCKT in Q3 2015 and has held it in 6 quarters since. The position peaked at $3.9M in Q4 2015. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

  • BlackRock Group held 36,652 shares of Rocket Pharmaceuticals worth $894K as of Q4 2016.
  • BlackRock Group sold 48,200 Rocket Pharmaceuticals shares in Q4 2016, an estimated $1.38M.
  • Rocket Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2180 holding.
  • BlackRock Group first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 6 quarters since.
  • BlackRock Group's Rocket Pharmaceuticals position peaked at $3.9M in Q4 2015.
  • 82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.